Attached files
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002
In connection with the Annual Report of
Tenax Therapeutics, Inc. (the
“Company”) on Form 10-K for the period year December
31, 2019 as filed with the Securities and Exchange Commission on
the date hereof (the “Report”), I, Michael B. Jebsen,
Chief Financial Officer (Principal Financial Officer) of the
Company, certify pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:
(1)
the Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and
(2)
the information contained in the Report fairly presents, in all
material respects, the financial condition and results of
operations of the Company.
|
Date: March 30, 2020
|
|
/s/ Michael B. Jebsen
|
|
|
|
|
|
Michael
B. Jebsen
|
|
|
|
|
|
Chief Financial Officer
(Principal Financial Officer)
|
|
|
|
|
|
|
|
|
The foregoing certification is being furnished solely to accompany
the Report pursuant to 18 U.S.C. Section 1350 and is not being
filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and is not to be incorporated by reference
into any filing of the Company, whether made before or after the
date hereof, regardless of any general incorporation language in
such filing.
A signed original of this written statement required by Section 906
of the Sarbanes-Oxley Act of 2002 has been provided to the Company
and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.